Kirk Malloy Biography and Net Worth

Kirk D. Malloy, Ph.D. has served as a member of the board of directors since September 2016 and as a member of the compensation committee since May 2017. Dr. Malloy served as Chief Executive Officer of Verogen, Inc., from August 2017 to August 2018 after founding the company and securing initial funding. Dr. Malloy is currently founder and principal at BioAdvisors, LLC, where he provides strategic consulting services to life science, diagnostics, and genomics companies. Prior to founding BioAdvisors in April 2016, he was at Illumina, Inc. from 2002 to 2016, most recently as Senior Vice President and General Manager of Life Sciences and Applied Markets from January 2014 to April 2016. From May 2005 to December 2013 he served as Vice President of Global Customer Solutions; he was also Vice President of Global Quality from December 2005 to May 2007. Dr. Malloy joined Illumina in 2002 as Senior Director of Global Customer Solutions. Before Illumina, he held various commercial leadership positions at Biosite Diagnostics and QIAGEN Inc. Dr. Malloy currently serves as Chairman of the Board for Organovo, a publicly-traded company that designs and creates functional, three-dimensional human tissues for use in medical research and therapeutic applications. He also serves as a director for several private genomics tools companies. Dr. Malloy earned his B.S. in Biology from the University of Miami, and his M.S. and Ph.D. from the University of Delaware and held post-doctoral and instructor positions at Boston University and Northeastern University.

What is Kirk Malloy's net worth?: The estimated net worth of Kirk Malloy is at least $0.00 as of August 8th, 2024. Mr. Malloy owns 64,300 shares of NanoString Technologies stock worth more than $0 as of December 28th. This net worth evaluation does not reflect any other assets that Mr. Malloy may own. Learn More about Kirk Malloy's net worth.
How do I contact Kirk Malloy?: The corporate mailing address for Mr. Malloy and other NanoString Technologies executives is 530 FAIRVIEW AVENUE NORTH SUITE 2000, SEATTLE WA, 98109. NanoString Technologies can also be reached via phone at (888) 358-6266 and via email at [email protected]. Learn More on Kirk Malloy's contact information.
Has Kirk Malloy been buying or selling shares of NanoString Technologies?: Kirk Malloy has not been actively trading shares of NanoString Technologies during the past quarter. Most recently, Kirk Malloy sold 3,000 shares of the business's stock in a transaction on Monday, September 13th. The shares were sold at an average price of $59.37, for a transaction totalling $178,110.00. Following the completion of the sale, the director now directly owns 8,010 shares of the company's stock, valued at $475,553.70. Learn More on Kirk Malloy's trading history.
Who are NanoString Technologies' active insiders?: NanoString Technologies' insider roster includes K. Bailey (CFO), Joseph Beechem (SVP), Elisha Finney (Director), R. Gray (CEO), Robert Hershberg (Director), and Kirk Malloy (Director). Learn More on NanoString Technologies' active insiders.

Kirk Malloy Insider Trading History at NanoString Technologies

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/13/2021	Sell	3,000	$59.37	$178,110.00	8,010
8/16/2021	Sell	1,500	$55.82	$83,730.00	8,010
6/14/2021	Sell	168	$60.05	$10,088.40	1,158
5/10/2021	Sell	1,500	$63.65	$95,475.00	2,490
1/11/2021	Sell	2,500	$66.53	$166,325.00	1,990
11/9/2020	Sell	2,500	$40.96	$102,400.00	1,990
9/8/2020	Sell	3,400	$36.61	$124,474.00	3,390
8/11/2020	Sell	2,500	$35.97	$89,925.00	2,890
4/20/2020	Sell	1,500	$30.00	$45,000.00	1,500
4/15/2020	Sell	1,000	$25.61	$25,610.00	1,000
12/13/2019	Sell	1,000	$25.59	$25,590.00	1,000
10/15/2019	Sell	1,000	$22.00	$22,000.00	1,000
8/13/2019	Sell	1,000	$25.05	$25,050.00	1,000

Kirk Malloy Buying and Selling Activity at NanoString Technologies

NanoString Technologies Company Overview

NanoString Technologies, Inc. develops, manufactures, and sells technology for scientific and clinical information in the fields of genomics and proteomics in the Americas, Europe, the Middle East, and the Asia Pacific. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system. It provides nCounter Pro and FLEX systems that include Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples by taking images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files. The company also offers nCounter SPRINT Profiler, an instrument that provides liquid handling steps and the digital analysis through use of a microfluidic cartridge; and nSolver Analysis Software, a data analysis program that enables researchers to check, normalize, and analyze their data. In addition, it provides custom CodeSets; panels with oncology, immunology and infectious disease, and neuroscience applications. Further, the company offers Master Kits, cartridges, ancillary reagents, tips and reagent plates to setup and process samples in instruments; and Prosigna in vitro diagnostic kits. The company is also developing GeoMx DSP system to enable the field of spatial biology. It has collaboration with Lam Research Corporation for the development of NGS sequencing platform and related assays; and Parker Institute for Cancer Immunotherapy to develop CAR-T regimens that enhances patient outcomes for various types of cancer, as well as collaboration with Stanford Medicine, Acrobat Genomics, and Illumina Accelerator to discover new drug targets for gene editing-based therapeutics. NanoString Technologies, Inc. was incorporated in 2003 and is headquartered in Seattle, Washington. On February 4, 2024, NanoString Technologies, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Today's Range

Now: N/A

50 Day Range

MA: $0.36

$0.05

$0.80

2 Week Range

Now: N/A

Volume

23,061,200 shs

Average Volume

34,541,648 shs

Market Capitalization

$5.07 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.24

Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong

From Brownstone Research | Ad

Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.

Click here to watch this demo and decide for yourself.